Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 11, No. 10, 1089-1094, November 2006; doi:10.1634/theoncologist.11-10-1089
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pectasides, D.
Right arrow Articles by Economopoulos, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pectasides, D.
Right arrow Articles by Economopoulos, T.

Gynecologic Oncology

Treatment Issues in Clear Cell Carcinoma of the Ovary: A Different Entity?

Dimitrios Pectasides, Eirini Pectasides, Amanda Psyrri, Theofanis Economopoulos

Second Department of Internal Medicine, Oncology Section, University of Athens, "Attikon" University Hospital, Athens, Greece

Correspondence: Dimitrios Pectasides, M.D., Gravias 5B, Aghia Paraskevi, Athens 15342, Greece. Telephone & Fax: 30210-600-8610; e-mail: pectasid{at}otenet.gr

Background. Ovarian clear cell carcinoma (OCCC) is a distinct histopathologic subtype of epithelial ovarian cancer (EOC) with an incidence of <5% of all ovarian malignancies. Our goal was to review the clinical features and management of patients with OCCC.

Methods and Results. We performed a PubMed search using the phrase "clear cell ovarian cancer." We reviewed 54 articles referring to OCCC. OCCC patients have a high incidence of stage I disease and frequently present with a large pelvic mass. Recurrences are more frequent with this entity than with other types of EOC. The clinical management of advanced EOC includes maximal cytoreduction and platinum plus paclitaxel–based chemotherapy. The survival rates of patients with advanced OCCC are lower than those of patients with advanced serous EOC (serous subtype). The poor response rate to platinum-based regimens may be related to the intrinsic chemoresistance of these tumors. Despite their aggressive clinical course, OCCCs are still treated similarly to the other EOCs at the present time, because the rarity of these tumors prevents the conduction of randomized studies.

Conclusion. Novel treatment approaches should be adopted in OCCC. Molecular-targeted therapies and effective new agents without cross-resistance to platinum compounds should be evaluated in a prospective clinical trial in OCCC.




This article has been cited by other articles:


Home page
 Mol. Endocrinol.Home page
A. K. Nagaraja, C. J. Creighton, Z. Yu, H. Zhu, P. H. Gunaratne, J. G. Reid, E. Olokpa, H. Itamochi, N. T. Ueno, S. M. Hawkins, et al.
A Link between mir-100 and FRAP1/mTOR in Clear Cell Ovarian Cancer
Mol. Endocrinol., February 1, 2010; 24(2): 447 - 463.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
D. PECTASIDES, G. PAPAXOINIS, G. FOUNTZILAS, G. ARAVANTINOS, A. BAMIAS, N. PAVLIDIS, H.P. KALOFONOS, E. TIMOTHEADOU, E. SAMANTAS, E. BRIASOULIS, et al.
Epithelial Ovarian Cancer in Greece: A Retrospective Study of 1,791 Patients by the Hellenic Cooperative Oncology Group (HeCOG)
Anticancer Res, February 1, 2009; 29(2): 745 - 751.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2006 by AlphaMed Press.
Advertisement